Keywords: innexus, nhl, mab, shows, strong, safety, preclinical

InNexus' NHL MAb shows strong safety in preclinical studies

Article | 22 April 2009

Print This

Canadian drug developer InNexus says that its drug candidate DXL625 appears to be superior to commercial-stage antibodies in its ability ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in